| Mechanosensitive caveolin-1 activation-induced PI3K/Akt/mTOR signaling pathway promotes breast cancer motility, invadopodia formation and metastasis in vivo H Yang, L Guan, S Li, Y Jiang, N Xiong, L Li, C Wu, H Zeng, Y Liu Oncotarget 7 (13), 16227, 2016 | 134 | 2016 |
| Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma JF Liu, N Xiong, SM Campos, AA Wright, C Krasner, S Schumer, ... Journal of Clinical Oncology 39 (14), 1531-1539, 2021 | 108 | 2021 |
| MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial–mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells S Li, J Lu, Y Chen, N Xiong, L Li, J Zhang, H Yang, C Wu, H Zeng, Y Liu Cellular & molecular immunology 14 (7), 621-630, 2017 | 97 | 2017 |
| Involvement of caveolin-1 in low shear stress-induced breast cancer cell motility and adhesion: roles of FAK/Src and ROCK/p-MLC pathways N Xiong, S Li, K Tang, H Bai, Y Peng, H Yang, C Wu, Y Liu Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1864 (1), 12-22, 2017 | 66 | 2017 |
| Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial EK Lee, N Xiong, SC Cheng, WT Barry, RT Penson, ... Gynecologic Oncology 159 (1), 72-78, 2020 | 52 | 2020 |
| Notch-1 signaling activates NF-κB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway L Li, J Zhang, N Xiong, S Li, Y Chen, H Yang, C Wu, H Zeng, Y Liu Medical Oncology 33, 1-11, 2016 | 52 | 2016 |
| Acidic pHe regulates cytoskeletal dynamics through conformational integrin β1 activation and promotes membrane protrusion S Li, N Xiong, Y Peng, K Tang, H Bai, X Lv, Y Jiang, X Qin, H Yang, C Wu, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1864 (7 …, 2018 | 36 | 2018 |
| A phase II, two-stage study of Letrozole and Abemaciclib in estrogen receptor–positive recurrent endometrial cancer PA Konstantinopoulos, EK Lee, N Xiong, C Krasner, S Campos, DL Kolin, ... Journal of Clinical Oncology 41 (3), 599-608, 2023 | 31 | 2023 |
| Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer F Batalini, N Xiong, N Tayob, M Polak, J Eismann, LC Cantley, GI Shapiro, ... Clinical Cancer Research 28 (8), 1493-1499, 2022 | 31 | 2022 |
| Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer PA Konstantinopoulos, AA Gockley, N Xiong, C Krasner, N Horowitz, ... JAMA oncology 8 (9), 1317-1322, 2022 | 25 | 2022 |
| Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers F Batalini, DC Gulhan, V Mao, A Tran, M Polak, N Xiong, N Tayob, ... Clinical Cancer Research 28 (21), 4714-4723, 2022 | 21 | 2022 |
| Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer RA Pozzar, N Xiong, F Hong, AA Wright, BA Goff, ML Underhill-Blazey, ... Gynecologic oncology 163 (2), 408-418, 2021 | 21 | 2021 |
| Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: results from a multi-site randomized trial DL Berry, F Hong, TM Blonquist, B Halpenny, N Xiong, CP Filson, ... Urologic Oncology: Seminars and Original Investigations 39 (8), 493. e9-493. e15, 2021 | 16 | 2021 |
| Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours RB Corcoran, KT Do, JM Cleary, AR Parikh, OO Yeku, CD Weekes, ... Annals of Oncology 30, v164, 2019 | 16 | 2019 |
| Clinical decision support for symptom management in lung cancer patients: a group RCT ME Cooley, E Mazzola, N Xiong, F Hong, DF Lobach, IM Braun, ... Journal of pain and symptom management 63 (4), 572-580, 2022 | 13 | 2022 |
| A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma EH Stover, N Xiong, AP Myers, N Tayob, V Engvold, M Polak, ... Gynecologic Oncology Reports 40, 100974, 2022 | 11 | 2022 |
| LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer PA Konstantinopoulos, AA Gockley, N Xiong, N Tayob, CN Krasner, ... Annals of Oncology 31, S1165, 2020 | 11 | 2020 |
| A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma. JF Liu, N Xiong, SM Campos, AA Wright, CN Krasner, ST Schumer, ... Journal of Clinical Oncology 38 (15_suppl), 6009-6009, 2020 | 10 | 2020 |
| Mixed‐methods analysis of decisional regret in parents following a child's death from cancer D Feifer, EG Broden, N Xiong, E Mazzola, JN Baker, J Wolfe, JM Snaman Pediatric Blood & Cancer 70 (10), e30541, 2023 | 9 | 2023 |
| Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer RA Pozzar, F Hong, N Xiong, JE Stopfer, MM Nayak, M Underhill-Blazey Familial Cancer, 1-13, 2021 | 7 | 2021 |
